Order Article Reprints

Kobayashi IS, Viray H, Rangachari D, Kobayashi SS, Costa DB. EGFR-D770>GY and Other Rare EGFR Exon 20 Insertion Mutations with a G770 Equivalence Are Sensitive to Dacomitinib or Afatinib and Responsive to EGFR Exon 20 Insertion Mutant-Active Inhibitors in Preclinical Models and Clinical Scenarios. Cells. 2021; 10(12):3561. https://doi.org/10.3390/cells10123561

Kobayashi, Ikei S., Hollis Viray, Deepa Rangachari, Susumu S. Kobayashi, and Daniel B. Costa. 2021. "EGFR-D770>GY and Other Rare EGFR Exon 20 Insertion Mutations with a G770 Equivalence Are Sensitive to Dacomitinib or Afatinib and Responsive to EGFR Exon 20 Insertion Mutant-Active Inhibitors in Preclinical Models and Clinical Scenarios" Cells 10, no. 12: 3561. https://doi.org/10.3390/cells10123561

Kobayashi, I. S., Viray, H., Rangachari, D., Kobayashi, S. S., & Costa, D. B. (2021). EGFR-D770>GY and Other Rare EGFR Exon 20 Insertion Mutations with a G770 Equivalence Are Sensitive to Dacomitinib or Afatinib and Responsive to EGFR Exon 20 Insertion Mutant-Active Inhibitors in Preclinical Models and Clinical Scenarios. Cells, 10(12), 3561. https://doi.org/10.3390/cells10123561